Tags

Type your tag names separated by a space and hit enter

Current and emerging pharmacotherapies for obesity in Australia.
Obes Res Clin Pract. 2017 Sep - Oct; 11(5):501-521.OR

Abstract

BACKGROUND

Obesity is a major issue in Australia and globally. Many individuals struggle to maintain weight loss with lifestyle modification, and adjunctive pharmacotherapy may help. Historically, there have been limited pharmacotherapies for managing obesity. In addition, previous treatments such as phentermine-fenfluramine, rimonabant and sibutramine were withdrawn due to safety issues, resulting in lingering safety concerns.

METHODS

This is a narrative review of published data examining four new pharmacotherapy options for weight management in Australia. Of four new therapeutic options, three may be approved in Australia shortly and one - liraglutide 3.0mg - was approved in December 2015. Liraglutide is a glucagon-like peptide-1 receptor agonist that appears to act by increasing satiety and reducing food intake. Lorcaserin is a selective agonist of the serotonin2C receptor, which mediates anorectic activity. The naltrexone/bupropion extended release (ER) combination utilises synergistic effects of the two component drugs, mediated via neurons in the hypothalamus, to reduce energy intake. Phentermine/topiramate ER combines the appetite suppressant phentermine with topiramate, an anti-epileptic with appetite-suppressant effects. All can result in meaningful improvements in obesity-related diseases, including diabetes and cardiovascular disorders) in large phase 3 trials, with efficacy demonstrated over 3 years for liraglutide 3.0 mg and 1-2 years for the rest.

CONCLUSIONS

The landscape of obesity treatment is changing rapidly. Of the new therapeutic options presented, all options have associated adverse events requiring long-term safety data, but the availability of new options is a welcome development.

Authors+Show Affiliations

Northern Clinical School, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia; Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW, Australia.Eastern Clinical Research Unit: Translational Research Division, Eastern Health Clinical School, Department of Medicine, Monash University, Level 2, 5 Arnold Street, Box Hill, VIC, Australia.Biomedicine Discovery Institute & Department of Physiology, Monash University, Building 13F, Clayton, 3800, VIC, Australia. Electronic address: michael.cowley@monash.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28818558

Citation

Hocking, Samantha, et al. "Current and Emerging Pharmacotherapies for Obesity in Australia." Obesity Research & Clinical Practice, vol. 11, no. 5, 2017, pp. 501-521.
Hocking S, Dear A, Cowley MA. Current and emerging pharmacotherapies for obesity in Australia. Obes Res Clin Pract. 2017;11(5):501-521.
Hocking, S., Dear, A., & Cowley, M. A. (2017). Current and emerging pharmacotherapies for obesity in Australia. Obesity Research & Clinical Practice, 11(5), 501-521. https://doi.org/10.1016/j.orcp.2017.07.002
Hocking S, Dear A, Cowley MA. Current and Emerging Pharmacotherapies for Obesity in Australia. Obes Res Clin Pract. 2017 Sep - Oct;11(5):501-521. PubMed PMID: 28818558.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current and emerging pharmacotherapies for obesity in Australia. AU - Hocking,Samantha, AU - Dear,Anthony, AU - Cowley,Michael A, Y1 - 2017/08/14/ PY - 2016/11/14/received PY - 2017/06/01/revised PY - 2017/07/07/accepted PY - 2017/8/19/pubmed PY - 2018/6/14/medline PY - 2017/8/19/entrez KW - Anti-obesity agents KW - Australia KW - Liraglutide 3.0mg KW - Orlistat KW - Phentermine SP - 501 EP - 521 JF - Obesity research & clinical practice JO - Obes Res Clin Pract VL - 11 IS - 5 N2 - BACKGROUND: Obesity is a major issue in Australia and globally. Many individuals struggle to maintain weight loss with lifestyle modification, and adjunctive pharmacotherapy may help. Historically, there have been limited pharmacotherapies for managing obesity. In addition, previous treatments such as phentermine-fenfluramine, rimonabant and sibutramine were withdrawn due to safety issues, resulting in lingering safety concerns. METHODS: This is a narrative review of published data examining four new pharmacotherapy options for weight management in Australia. Of four new therapeutic options, three may be approved in Australia shortly and one - liraglutide 3.0mg - was approved in December 2015. Liraglutide is a glucagon-like peptide-1 receptor agonist that appears to act by increasing satiety and reducing food intake. Lorcaserin is a selective agonist of the serotonin2C receptor, which mediates anorectic activity. The naltrexone/bupropion extended release (ER) combination utilises synergistic effects of the two component drugs, mediated via neurons in the hypothalamus, to reduce energy intake. Phentermine/topiramate ER combines the appetite suppressant phentermine with topiramate, an anti-epileptic with appetite-suppressant effects. All can result in meaningful improvements in obesity-related diseases, including diabetes and cardiovascular disorders) in large phase 3 trials, with efficacy demonstrated over 3 years for liraglutide 3.0 mg and 1-2 years for the rest. CONCLUSIONS: The landscape of obesity treatment is changing rapidly. Of the new therapeutic options presented, all options have associated adverse events requiring long-term safety data, but the availability of new options is a welcome development. SN - 1871-403X UR - https://www.unboundmedicine.com/medline/citation/28818558/Current_and_emerging_pharmacotherapies_for_obesity_in_Australia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1871-403X(17)30065-0 DB - PRIME DP - Unbound Medicine ER -